RIPOR2 and cervical cancer: On the other hand, we could not detect the RIPOR2 protein in tumor samples nor in cell lysates since the available commercial antibodies had poor immunodetection by western blot and immunohistochemistry; therefore, the obtention of more specific antibodies for the detection of RIPOR2 variants would be valuable to evaluate its association with poor OS in cervical cancer patients.